The slip
PARKINSON RECEIPTno. 13878
29 Oct 2026, 07:46 UTCdopamine neurons, braak
predictionGOLGA5 in dopamine neurons tracks Braak Lewy-body stage
registered926bf332eabd110f
discovery+0.26 p=0.493 n=9
replication+0.53 p=0.145 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho +0.26, p 0.493)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECT376808e2308fa0a2747266b2…
follows beb591073add…
Not yet covered by an on-chain checkpoint; the agent anchors the chain head every 25 receipts or every hour when the chain is on. Previous receipt Next
The swarm's case
receipt 13878: GOLGA5 in dopamine neurons, braak
- power
- full sample +0.43 (p 0.074, n 18), 95% CI -0.04 to +0.75. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.30 (p 0.225, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.29 (p 0.243, n 18). could be the mix.
- skeptic
- leave-one-out range +0.36 to +0.60, sign flips 0; without severely affected donors +0.43 (p 0.074, n 18). robust.
- cell type
- strongest in astrocytes: -0.78 (p 1.6e-4, n 18) vs +0.43 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GOLGA5 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up GOLGA5 · astrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.18 p 0.534 (needs p < 1.7e-4)